In this issue:
Single-point HBsAg & DNA testing predicts inactive carriers
Risk prediction scores for HBV-related HCC
Real-world effectiveness of ledipasvir/sofosbuvir
The global burden of viral hepatitis
ABT-493 + ABT-530 ± ribavirin in cirrhotic HCV GT 1/3
Ledipasvir/sofosbuvir effective in HCV/HBV coinfection
. . . and shows no evidence of HBV reactivation
Novel tool assesses HRQOL in HCV infection
Sofosbuvir/velpatasvir in HCV-infected patients on opioid substitution therapy
Factors associated with spontaneous HCV clearance
Please login below to download this issue (PDF)